]> 2026-04-12T02:27:18-07:00 CPT-11 (Irinotecan) 0 en While showing promise in efficacy, the combination treatments involving CPT-11 have been associated with manageable but significant toxicities, including hematologic, gastrointestinal, and hepatic adverse events. 2025-01-18T08:27:01Z 2460693.8520949 CPT-11 (Irinotecan) 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Investigations into CPT-11 for recurrent glioma, particularly in combination with other chemotherapy agents and targeted therapies, have demonstrated potential improvements in patient outcomes. These early phase trials underscore the importance of further research to optimize dosing, manage toxicities, and ultimately improve survival and quality of life for patients with recurrent malignant gliomas."] CPT-11 (Irinotecan)# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name